107 related articles for article (PubMed ID: 16933859)
1. Retrospective analysis of cord blood transplantation on 62 adult patients with advanced hematological malignancies.
Tamura K; Kawano F; Etoh T; Utsunomiya A; Imamura Y; Okamura S; Tsukada J; Uike N; Takamatsu Y;
Fukuoka Igaku Zasshi; 2006 Jun; 97(6):175-82. PubMed ID: 16933859
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of unrelated donor umbilical cord blood transplantation for 30 adults with hematological malignancies.
Kobayashi K; Maeda Y; Hara Y; Nishie-Kataoka M; Nishimori H; Sugiyama H; Namba N; Kubonishi S; Niiya M; Shinagawa K; Ikeda K; Tanimoto M
Anticancer Res; 2009 May; 29(5):1763-70. PubMed ID: 19443401
[TBL] [Abstract][Full Text] [Related]
3. Cord blood transplantation for adult patients with hematological malignancies.
Yamane T; Nakamae H; Hasegawa T; Terada Y; Hagihara K; Ohta K; Hino M
Osaka City Med J; 2005 Dec; 51(2):83-8. PubMed ID: 16617685
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies.
Mori T; Aisa Y; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Yamane A; Ikeda Y; Okamoto S
Transplant Proc; 2007 Jun; 39(5):1615-9. PubMed ID: 17580201
[TBL] [Abstract][Full Text] [Related]
5. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation.
Rodrigues CA; Sanz G; Brunstein CG; Sanz J; Wagner JE; Renaud M; de Lima M; Cairo MS; Fürst S; Rio B; Dalley C; Carreras E; Harousseau JL; Mohty M; Taveira D; Dreger P; Sureda A; Gluckman E; Rocha V
J Clin Oncol; 2009 Jan; 27(2):256-63. PubMed ID: 19064984
[TBL] [Abstract][Full Text] [Related]
6. Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis.
Yamada MF; Miyamura K; Fujiwara T; Kohata K; Okitsu Y; Ohguchi H; Yamamoto J; Yokoyama H; Tomiya Y; Ishizawa K; Kameoka J; Harigae H
Transplant Proc; 2008 Dec; 40(10):3637-42. PubMed ID: 19100456
[TBL] [Abstract][Full Text] [Related]
7. Myeloablative unrelated cord blood transplantation for acute leukemia patients between 50 and 55 years of age: single institutional retrospective comparison with patients younger than 50 years of age.
Konuma T; Takahashi S; Ooi J; Tomonari A; Tsukada N; Kato S; Sato A; Monma F; Kasahara S; Nagamura-Inoue T; Uchimaru K; Iseki T; Tojo A; Yamaguchi T; Asano S
Ann Hematol; 2009 Jun; 88(6):581-8. PubMed ID: 19030858
[TBL] [Abstract][Full Text] [Related]
8. Unrelated cord blood transplantation after myeloablative conditioning in adults with acute myelogenous leukemia.
Ooi J; Takahashi S; Tomonari A; Tsukada N; Konuma T; Kato S; Kasahara S; Sato A; Monma F; Nagamura F; Iseki T; Tojo A; Asano S
Biol Blood Marrow Transplant; 2008 Dec; 14(12):1341-7. PubMed ID: 19041055
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of 122 diverse adult and pediatric cord blood transplant recipients from a large cord blood bank.
Ballen KK; Haley NR; Kurtzberg J; Lane TA; Lindgren BR; Miller JP; Newman B; McCullough J
Transfusion; 2006 Dec; 46(12):2063-70. PubMed ID: 17176317
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases.
Miyakoshi S; Kami M; Tanimoto T; Yamaguchi T; Narimatsu H; Kusumi E; Matsumura T; Takagi S; Kato D; Kishi Y; Murashige N; Yuji K; Uchida N; Masuoka K; Wake A; Taniguchi S
Transplantation; 2007 Aug; 84(3):316-22. PubMed ID: 17700155
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
12. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.
Maruyama D; Fukuda T; Kato R; Yamasaki S; Usui E; Morita-Hoshi Y; Kim SW; Mori S; Heike Y; Makimoto A; Tajima K; Tanosaki R; Tobinai K; Takaue Y
Biol Blood Marrow Transplant; 2007 Aug; 13(8):932-41. PubMed ID: 17640597
[TBL] [Abstract][Full Text] [Related]
13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
14. Unrelated cord blood transplantation after myeloablative conditioning in adults with ALL.
Ooi J; Takahashi S; Tomonari A; Tsukada N; Konuma T; Kato S; Kasahara S; Sato A; Monma F; Nagamura F; Iseki T; Tojo A; Asano S
Bone Marrow Transplant; 2009 Mar; 43(6):455-9. PubMed ID: 18955981
[TBL] [Abstract][Full Text] [Related]
15. Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study.
Gutierrez-Aguirre CH; Gomez-Almaguer D; Cantu-Rodríguez OG; Gonzalez-Llano O; Jaime-Perez JC; Herena-Perez S; Manzano CA; Estrada-Gomez R; Gonzalez-Carrillo ML; Ruiz-Argüelles GJ
Bone Marrow Transplant; 2007 Sep; 40(6):535-9. PubMed ID: 17618317
[TBL] [Abstract][Full Text] [Related]
16. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
17. Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan.
Komatsu T; Narimatsu H; Yoshimi A; Kurita N; Kusakabe M; Hori A; Murashige N; Matsumura T; Kobayashi K; Yuji K; Tanaka Y; Kami M
Ann Hematol; 2007 Jan; 86(1):49-54. PubMed ID: 17036221
[TBL] [Abstract][Full Text] [Related]
18. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
Rodriguez R; Nademanee A; Ruel N; Smith E; Krishnan A; Popplewell L; Zain J; Patane K; Kogut N; Nakamura R; Sarkodee-Adoo C; Forman SJ
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1326-34. PubMed ID: 17162215
[TBL] [Abstract][Full Text] [Related]
19. Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults.
Narimatsu H; Terakura S; Matsuo K; Oba T; Uchida T; Iida H; Hamaguchi M; Watanabe M; Kohno A; Murata M; Sawa M; Miyamura K; Morishita Y
Bone Marrow Transplant; 2007 Jan; 39(1):31-9. PubMed ID: 17115066
[TBL] [Abstract][Full Text] [Related]
20. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation.
Mohty M; Labopin M; Tabrizzi R; Theorin N; Fauser AA; Rambaldi A; Maertens J; Slavin S; Majolino I; Nagler A; Blaise D; Rocha V; ;
Haematologica; 2008 Feb; 93(2):303-6. PubMed ID: 18245655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
